Lupin gets USFDA nod to market generic lung disease treatment capsule, ET HealthWorld


New Delhi: Pharma major Lupin Ltd on Tuesday said it received approval from the US health regulator to market its generic Pirfenidone capsules used for the treatment of lung disease known as idiopathic pulmonary fibrosis.

The approval granted by the US Food and Drug Administration (USFDA) is for the abbreviated new drug application for Pirfenidone capsules of 267 mg strength, Lupin said in a regulatory filing.

The drug is the generic equivalent of Esbriet Capsules, 267 mg of Hoffmann La Roche Inc.

This product will be manufactured at Lupin’s Pithampur facility in India, it added.

Pirfenidone capsules had estimated annual sales of USD 95 million in the US, Lupin said citing IQVIA MAT June 2023 data.

  • Published On Aug 30, 2023 at 05:54 PM IST

Join the community of 2M+ industry professionals

Subscribe to our newsletter to get latest insights & analysis.

Download ETHealthworld App

  • Get Realtime updates
  • Save your favourite articles

Scan to download App


Leave a Reply

Your email address will not be published. Required fields are marked *